Omacetaxine mepesuccinate

Drug Profile

Omacetaxine mepesuccinate

Alternative Names: Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; Synribo

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
  • Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Alkaloids; Harringtonines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies; Solid tumours
  • Discontinued Acute promyelocytic leukaemia

Most Recent Events

  • 01 Jan 2017 The M.D. Anderson Cancer Center and Cephalon completes a phase II trial for Acute myeloid leukaemia or Myelodysplastic syndromes in USA (NCT01272245)
  • 15 Mar 2016 Biomarkers information updated
  • 04 Feb 2016 Roswell Park Cancer Institute terminates a phase-II clinical trial in Acute myeloid leukaemia (Combination therapy, In the elderly, Newly diagnosed, First-line therapy) in USA (NCT02029417)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top